The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Open accessAbstract
Importance: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. Objective: To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer. Design, Setting, and Participants: Patients (≥18 years) enrolled at community and academic centers throughout the National Clinical Trials Network in the United States and Canada (November 2005-March 2012) with previously untreated advanced or metastatic colorectal cancer whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or bevacizumab (n = 559). The last date of follow-up was December 15, 2015. Interventions: Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient. Main Outcomes and Measures: The primary end point was overall survival. Secondary objectives included progression-free survival and overall response rate, site-reported confirmed or unconfirmed complete or partial response. Results: Among 1137 patients (median age, 59 years; 440 [39%] women), 1074 (94%) of patients met eligibility criteria. As of December 15, 2015, median follow-up for 263 surviving patients was 47.4 months (range, 0-110.7 months), and 82% of patients (938 of 1137) experienced disease progression. The median overall survival was 30.0 months in the cetuximab-chemotherapy group and 29.0 months in the bevacizumab-chemotherapy group with a stratified hazard ratio (HR) of 0.88 (95% CI, 0.77-1.01; P = .08). The median progression-free survival was 10.5 months in the cetuximab-chemotherapy group and 10.6 months in the bevacizumab-chemotherapy group with a stratified HR of 0.95 (95% CI, 0.84-1.08; P = .45). Response rates were not significantly different, 59.6% vs 55.2% for cetuximab and bevacizumab, respectively (difference, 4.4%, 95% CI, 1.0%-9.0%, P = .13). Conclusions and Relevance: Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment. Trial Registration: clinicaltrials.gov identifier: NCT00265850.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, patients with metastatic colorectal cancer and related intestinal malignancies tend to receive similar treatments and live for many months with relatively stable health (median overall survival >2 years) [44], facilitating study completion and potentially derivation of durable benefit from the intervention.”
From Being present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers (2018) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although a higher percentage of men enrolled compared to most prior mindfulness interventions for integrative cancer care [34], the evaluable study sample included a greater proportion of younger (age <50), female, White and Latino or Hispanic patients relative to the underlying population [44, 53].”
From Being present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers (2018) · cites this paper as [44]
Experimental — accuracy not yet measuredIn the citing paper
“This trial demonstrated that patients in the cetuximab plus chemotherapy group had slightly higher overall survival versus patients in the bevacizumab plus chemotherapy group (30.0 months versus 29.0 months).”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [65]
In the citing paper
“Similar to the FIRE-3 trial, median progression-free survival and response rates were similar between groups.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [65]
In the citing paper
“Similarly, the CALGB/SWOG 80405 trial showed that both cetuximab and bevacizumab provided comparable outcomes when combined with chemotherapy in the overall population, but the benefit of anti-EGFR therapy was again limited to RAS wild-type tumors [21].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [21]
In the citing paper
“however, it must be noted here that this pooled analysis also included patients who had received a nonstandard treatment regimen, including FUFIRI, FUFOX, and mIROX as induction chemotherapies and bevacizumab monotherapy or observation alone as maintenance therapies in clinical trials [22,23].”
From The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 2×
“dence indicated that cetuximab activity was unrelated to tumor expression of EGFR.(8) Bevacizumab, a humanized”
BackgroundThe consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“a The 0-to-5 coded scale describing patient daily level of functioning from fully active (0) to completely disabled (4); dead (5).”
BackgroundDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 4×
“Results are reported for (1) the primary 2-group comparison between cetuximab and bevacizumab; (2) the comparison of cetuximab vs bevacizumab in an expanded RAS subset described above; and (3) the chemotherapy subgroups.”
MethodInfluentialSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Cited by
Sorted by citations
Items 801–900 of 900
First Line Chemotherapy in Metastatic Colorectal Cancers: A Review
Colombo, A., Bordonaro, R., Sciacchitano, T., & Porretto, C. M. (2024) · International Journal of Advanced Multidisciplinary Research and Studies · doi:10.62225/2583049x.2024.4.2.2556
Chen, Y.-C., Chang, T., Su, W., Yeh, Y., Chen, P.-J., Huang, P.-J., Yang, P.-H., Tsai, H., Wang, J., & Huang, C. (2024) · Research Square · doi:10.21203/rs.3.rs-4516245/v1
“[5, 6] Although the application of standard targeted therapy plus chemotherapy yielded response rates of 55–60% for mCRC,[11] this success raises a clinical question: In a scenario where an asymptomatic synchronous mCRC patient receives standard systemic therapy and exhibits tumor shrinkage in both…”
Vitali, F., Merkel, S., Schubart, C., Schmid, A., Eckstein, M., Stöhr, R., Kersting, S., Hartmann, A., Grützmann, R., & Wein, A. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001636
Doğan, E., Fırat, S. T., Eser, M., Bozkurt, O., İnanç, M., & Özkan, M. (2024) · Istanbul Medical Journal · doi:10.4274/imj.galenos.2024.78278
“OS was 30 months in the cetuximab and 29 months in the bevacizumab groups in the CALGB/SWOG 80405 study (14).”
Wehrle, C. J., Sarioglu, A. G., Akgun, E., & Berber, E. (2024) · Surgery · doi:10.1016/j.surg.2024.07.070
Hu, Q., Zhou, X., & Sun, Y. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae257
How to treat liver metastases in colorectal cancer: A review
Colombo, A., & Porretto, C. M. (2024) · International Journal of Gastrointestinal Intervention · doi:10.18528/ijgii240046
“28 Multidisciplinary team (MDT) should reevaluate liver metastases for NED eligibility two months after initiating systemic medication, and should promptly offer locoregional treatment, including surgical removal, if appropriate.”
Tougeron, D., Emile, J., Bodère, A., Barbier, E., Perrier, H., Corbinais, S., Brun-Ly, V. L., Bideau, K., Chibaudel, B., Khemissa, F., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5046191
Galmarini, C. M., Zamora, R., del Campo, P. G., Izquierdo, J. C., All, J. D., & Domı́nguez, J. M. (2024) · medRxiv · doi:10.1101/2024.12.18.24319211
Guo, Z., He, L., Wang, W., Tian, S., & Lin, R. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5074878
Pakvisal, N., Goldberg, R. M., Sathitruangsak, C., Silaphong, W., Faengmon, S., Teeyapun, N., Teerapakpinyo, C., & Tanasanvimon, S. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i3.102076
Self-citationLebedeva, A., Byakhova, M. M., Покатаев, И. А., Antonova, T. G., Ivanov, M. V., Semenova, A. B., Makiev, G. G., Kravchuk, D. A., Евдокимов, В. И., Большакова, Е. А., et al. (2025) · Malignant tumours · doi:10.18027/2224-5057-2024-030
Overall Survival in the CAIRO5 Clinical Trial
Ballhausen, A., & Modest, D. P. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.0604
Ceylan, F., Esen, S. A., Ünal, O. Ü., Aslan, F., Onur, İ. D., Ateş, Ö., Demırcıler, E., Ünek, İ. T., Gülmez, A., Engin, E. Ö., et al. (2025) · Medicina · doi:10.3390/medicina61050776
“Previous landmark studies, including FIRE-3 [21] and CALGB/SWOG 80405 [22], demonstrated that incorporating biological therapies into fluorouracil-based treatment provided a survival advantage in RAS wild-type mCRC.”
Ahluwalia, M., Parmar, A., Loree, J. M., O'Callaghan, C. J., Tu, D., Chan, K., Jonker, D. J., Mittmann, N., Cheung, M. C., Feilotter, H., et al. (2025) · Value in Health · doi:10.1016/j.jval.2025.04.2159
Novel treatment-specific causal biomarkers for colorectal cancer by omics integration
Yazdani, A., Yazdani, A., Méndez-Giráldez, R., Pillonetto, G., Samiei, E., Hadi, R., Lenz, H., Venook, A. P., Samiei, A., Nixon, A. B., et al. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaf053
Self-citationPark, J., Kim, J., Nam, J. H., Kim, Y., Kim, J. W., Kang, S. H., Lim, Y., Kim, K., & Lee, K. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07575-1
Zheng, T., Li, X., Zhou, L., & Jin, J.-J. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i8.106873
Su, Y., Su, C., Lee, P., & Wu, C. (2025) · Annals of Coloproctology · doi:10.3393/ac.2025.00087.0012
“In the CALGB 80405 trial, no significant difference in over-all survival (OS) was observed between the cetuximab and bevacizumab treatment groups [7]; however, the FIRE-3 trial results indicated that the cetuximab group achieved significantly superior OS [8].”
Magge, T., Cheng, S., Wang, S., Syed, M. P., Jambunathan, B., McFarquhar, A., Peniche, P. Z., Baytar, D. K., Singhi, A. D., Saeed, A., et al. (2025) · Cancers · doi:10.3390/cancers17223677
Kim, H., Hong, J., Kong, S., & Choi, M. K. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1907944
Biswas, G., Goyal, S., Rauthan, A., Naqvi, S. M. H., Yadagiri, S. K. Y., Dhanaki, G. D., Sanghavi, A. P., Kumar, R., Katare, S., & Kotak, B. P. (2025) · Cureus · doi:10.7759/cureus.97914
“Additionally, the findings of the CAIRO5, FIRE-3, and CALGB/SWOG 80405 studies also showed that in patients with tumors on the left side, the PFS did not differ significantly between anti-EGFR and anti-VEGF therapy [50-52].”
Antonova, T. G., Михайловна, Б. М., Покатаев, И. А., Semenova, A. B., Большакова, Е. А., Стативко, О. А., Носова, М. В., Lebedeva, A., Kuzmina, E., Lyadova, M. A., et al. (2025) · Malignant tumours · doi:10.18027/2224-5057-2025-15-3s1-4-10
Covariate‐Adjusted Group Sequential Comparisons of Survival Probabilities
Zhang, P., Logan, B. R., & Martens, M. J. (2025) · Statistics in Medicine · doi:10.1002/sim.70339
Kagawa, Y., Osaka, T., Imamura, T., & Kuwabara, H. (2025) · Cancers · doi:10.3390/cancers17243962
“Similarly, the efficacy of EGFR inhibitors in RAS wild-type CRC is well established [31–33].”
Liang, L., Liu, M., Sun, X., Yuan, Y., Peng, K., Rashid, K., Yu, Y., Yuehong, C., Chen, Y., & Liu, T. (2021) · Figshare · doi:10.6084/m9.figshare.14432207
Quintanilha, J. C. F., Sibley, A. B., Liu, Y., Niedzwiecki, D., Halabi, S., Rogers, L. W., O’Neil, B. H., Kindler, H. L., Kelly, W. K., Venook, A. P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25824830
Self-citationGeng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716978
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716990
Liang, L., Liu, M., Sun, X., Yuan, Y., Peng, K., Rashid, K., Yu, Y., Yuehong, C., Chen, Y., & Liu, T. (2021) · Figshare · doi:10.6084/m9.figshare.14432198
Liu, H., Liu, H., Zhou, Z., Chung, J., Zhang, G., Chang, J., Parise, R. A., Chu, E., & Schmitz, J. C. (2023) · Figshare · doi:10.6084/m9.figshare.23542987
Smabers, L. P., Wensink, G. E., Veríssimo, C. S., Koedoot, E., Pitsa, K.-C., Huismans, M. A., Barón, C. H., Doorn, M., Iersel, L. V., Cirkel, G. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25302930
Ribera, I., & Faille, A. (2010) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.198606
Nishizawa, Y., Haraguchi, N., Kim, H., Ide, Y., Nakata, K., Okamura, S., Kudo, T., Satoh, T., Uemura, M., Matsuda, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16417391
Nishizawa, Y., Haraguchi, N., Kim, H., Ide, Y., Nakata, K., Okamura, S., Kudo, T., Satoh, T., Uemura, M., Matsuda, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16417400
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716993
Nishizawa, Y., Haraguchi, N., Kim, H., Ide, Y., Nakata, K., Okamura, S., Kudo, T., Satoh, T., Uemura, M., Matsuda, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16417388
Quintanilha, J. C. F., Sibley, A. B., Liu, Y., Niedzwiecki, D., Halabi, S., Rogers, L. W., O’Neil, B. H., Kindler, H. L., Kelly, W. K., Venook, A. P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25824646
Self-citationLiang, L., Liu, M., Sun, X., Yuan, Y., Peng, K., Rashid, K., Yu, Y., Yuehong, C., Chen, Y., & Liu, T. (2021) · Figshare · doi:10.6084/m9.figshare.14432201
Liu, H., Liu, H., Zhou, Z., Chung, J., Zhang, G., Chang, J., Parise, R. A., Chu, E., & Schmitz, J. C. (2023) · Figshare · doi:10.6084/m9.figshare.23542984
Song, Y., Mao, Q., Zhou, M., Liu, C.-J., Kong, L., & Hu, T. (2024) · Figshare · doi:10.6084/m9.figshare.25132128
Nishizawa, Y., Haraguchi, N., Kim, H., Ide, Y., Nakata, K., Okamura, S., Kudo, T., Satoh, T., Uemura, M., Matsuda, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16417385
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716984
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716981
Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Figshare · doi:10.6084/m9.figshare.26716987
Liang, L., Liu, M., Sun, X., Yuan, Y., Peng, K., Rashid, K., Yu, Y., Yuehong, C., Chen, Y., & Liu, T. (2021) · Figshare · doi:10.6084/m9.figshare.14432204
Nishizawa, Y., Haraguchi, N., Kim, H., Ide, Y., Nakata, K., Okamura, S., Kudo, T., Satoh, T., Uemura, M., Matsuda, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16417382
Nishizawa, Y., Haraguchi, N., Kim, H., Ide, Y., Nakata, K., Okamura, S., Kudo, T., Satoh, T., Uemura, M., Matsuda, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16417394
Ramzy, G. M., Norkin, M., Koessler, T., Voirol, L., Tihy, M., Hany, D., McKee, T., Ris, F., Nicolas, B., Docquier, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26579948
Lin, Z. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04921-2
Tatlıdede, D., Arslan, C., Yıldırım, M. E., Işıkdoğan, A., Karadurmuş, N., Karabulut, B., Çubukçu, E., Çiçin, İ., Yalçın, Ş., Türk, H. M., et al. (2026) · Anadolu Kliniği Tıp Bilimleri Dergisi · doi:10.21673/anadoluklin.1675424
Kontiainen, J., Lehtomäki, K., Muhonen, T. T., Hahl, J., Toppila, I., Poussa, T. A., Österlund, E., Heervä, E., Stedt, H., Kallio, R., et al. (2026) · Acta Oncologica · doi:10.2340/1651-226x.2026.45005
“The emergence of new treatments has led to improved survival in both operative and non-operative management [11–14].”
Vitamin C in the Treatment of Colorectal Cancer: Between Hope and Despair
Wasmer, M., Weber, M., & Faes, S. (2026) · Cancers · doi:10.3390/cancers18040654
“A phase Ib study has been designed to evaluate safety and effectiveness of botensilimab and balstilimab combined with a fasting-mimicking diet and high-dose vitamin C in patients with advanced CRC harboring KRAS mutations [103].”
Angelis, M. T. D., Santamaria, G., Amaddeo, A., Iannello, A. M., Viglietto, G., & Rizzuto, A. (2026) · Surgical Oncology · doi:10.1016/j.suronc.2026.102382
CHEN, Y.-H., Wu, C., Su, C., Lee, P.-T., & Su, Y. (2026) · Annals of Coloproctology · doi:10.3393/ac.2025.00759.0108
Tatlıdede, D., Arslan, Ç., Yıldırım, M. E., Işıkdoğan, A., Karadurmuş, N., Karabulut, B., Çubukçu, E., Çiçin, İ., Yalçın, Ş., Türk, H. M., et al. (2025) · DergiPark (Istanbul University)
Özdemir, A., Özdemir, E. Y., Göksu, S. S., Karaca, M., & Tatlı, A. M. (2026) · Akdeniz Medical Journal · doi:10.53394/akd.1585019
Chen, X., Liu, C., & Liao, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1783342
Yalçıner, M., Örüncü, M. B., Kayaalp, M., Erdat, E. C., Kavak, E. E., & Utkan, G. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072599
“…the addition of targeted therapies including anti-vascular endothelial growth factor (VEGF) and anti-epidermal growth factor receptor (EGFR) agents [5], BRAF inhibitors [6], and immune checkpoint inhibitors for microsatellite instability-high (MSI-H) tumors [7], with treatment selection…”
Shintani, H., Tokuhara, K., & Kataoka, N. (2026) · International Journal of Surgery Case Reports · doi:10.1097/rc9.0000000000000382
“Systemic chemotherapy remains the cornerstone of treatment for stage IV colorectal cancer [ 1 , 2 ] , and the integration of molecularly targeted agents has further improved clinical outcomes [ 3 , 4 ] .”
Two Decades of Multimodal Management of Colorectal Liver Metastases With Long‐Term Outcomes
Mohtashami, A., Shrestha, P., Chen, S. C. ‐., Vrisakis, J.-L., Bhimani, N., Pavlakis, N., Clarke, S. J., Diakos, C. I., Wong, M., & Hugh, T. J. (2026) · ANZ Journal of Surgery · doi:10.1111/ans.70658
Yang, W., Zhang, L., Liang, P., Qian, Z., Wang, D., Zhang, W., Li, B., Cui, C., Zhong, X., Wu, G., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02634-3 · Cited by 1
Munster, A. B., Mahmood, U., Fuller, H., Seo, H., Murphy, J., Menon, K., Imber, C. J., Bhan, C., & Khan, K. H. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103139
Lu, Y., Liu, J. B., Li, Y., xiang, L., Song, G.-B., Peng, T., Wang, Z., Yang, X., Ying, H., & Cheng, X.-X. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08812-z
“The liver is the most frequent site of CRC metastasis, largely due to the direct drainage of mesenteric venous blood into the portal vein [3, 4].”
Gene-level and global genomic insights into colorectal cancer ovarian metastasis
Fang, Y., Sun, Y., Li, N., Zhao, X., Wu, X., Pang, J., Ou, Q., Bao, H., Chen, C., & Xu, Z. (2026) · European journal of medical research · doi:10.1186/s40001-026-04389-7
“Women patients with CRC OM had a median overall survival (OS) of approximately 19 months [4], which is unfavorable when compared to the overall OS of women patients with CRC metastasizing to other sites [5].”
Grancher, A., Landi, M., Ballhausen, A., Tocino, R. V., Alig, A. H. S., Taravella, A., Malicot, K. L., Soularue, É., Gallois, C., Guarssifi, M., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.04.009
Ma, Z., Zhu, K., Shi, F., Feng, R., Jiang, S., Dou, X., Liu, J. T., Niu, Z., & Yue, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1622828
Özdemir, Ö., Günenç, D., Taşkaynatan, H., Peker, P., Kahraman, E. G., Biter, S., Paydaş, S., Önder, T., Ateş, Ö., Er, M. M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103979
“…decades, the treatment landscape for metastatic colorectal cancer (mCRC) has substantially improved, particularly with the introduction of targeted therapies, such as anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and anti-vascular endothelial growth factor (VEGF) agents [2–6].”
Jehanno, L., Henriques, J., Samaille, T., Loisel, C., Cervantes, B., Colle, R., Vernerey, D., André, T., & Cohen, R. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.05.003
Yamada, T., Nagasaka, T., Matsuhashi, N., Takahashi, T., Hirata, K., Nakamura, Y., Sugimoto, K., Koda, K., Hiramatsu, K., Matsuoka, H., et al. (2026) · Cancers · doi:10.3390/cancers18111688
Martins, M. P. R., Andrade, R. L. D. F., Delfino, P. H. V., do Amaral, L. R., Braga, L. D. C., & Martins‐Chaves, R. R. (2026) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-026-03468-3
EGFR deletion in myeloid cells reprograms the immunosuppressive landscape of colorectal cancer
Fari, O., Neuhofer, A., Holcmann, M., Chontorotzea, T., Barozzi, I., Mohr, T. T., Blauensteiner, B., Krauß, D., Xiao, Y., Lang, M., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01774-x
Prognostic understanding interventions in patients with advanced cancer: a systematic review
Dong, L., Tao, L., Wang, Y., Shi, M., Cheng, C., & Li, L. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2026.1824994
“Compared to patients with advanced pancreatic cancer, those with advanced colorectal cancer generally have a better prognosis, with up to 10–20% surviving beyond 5 years (Loupakis et al., 2014; Venook et al., 2017).”
Personalisierte Arzneimitteltherapie des kolorektalen Karzinoms
Schulte, N. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02133-1
Iguchi, K., Yamazaki, K., Misumi, T., Bando, H., Nishimura, Y., Nishikawa, T., Oki, E., Douillard, J.-Y., Koopman, M., Cutsem, E. V., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116886
Self-citationJang, J. Y., Lim, H., Ko, J., Lee, J. H., Kim, Y., Ah, S., Yoo, G. S., Park, H. C., Kim, N., Cho, Y. B., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16312-8
“The use of bevaci-zumab and cetuximab also increased during the study period, consistent with the incorporation of targeted agents into routine colorectal cancer care after pivotal clinical trials demonstrated survival benefits in metastatic disease [28, 29].”
Enhancing Targeted Colorectal Cancer Therapies with Natural Products: Mechanistic Pathways
Armega-Anghelescu, A., Vlad, D. C., Muntean, C., Flangea, C., Baderca, F., Mituletu, M., Vlad, T., & Dumitraşcu, V. (2026) · Biomedicines · doi:10.3390/biomedicines14071448
“…surge that drives acquired resistance to bevacizumab and regorafenib, providing a mechanistically rational basis for combining these phytochemicals as adjuvants to bevacizumab + FOL-FOX/FOLFIRI in first-line mCRC and to aflibercept-or regorafenib-based regimens after progression [42,50–52 , 55– 58”
Arai, H., Elliott, A., Yang, Y., Farrell, A. P., Millstein, J., Ou, F., Innocenti, F., Wang, J., Battaglin, F., Jayachandran, P., et al. (2026) · Oncogene · doi:10.1038/s41388-026-04019-w
Self-citationColorectal cancer liver metastases: mechanism and therapy
Liu, S., Ban, L.-X., Zhang, W., Sun, Y., Wang, K., Man, Y., & Zhang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1861130
Yu, J., Zhang, J., & Yang, S. S. (2026) · EXPLORE · doi:10.1016/j.explore.2026.103497
A Colon Cancer Organoid-on-a-Chip Model for In Vitro Therapy Assessment
Valle, L. G., Ortega, L., Heras, M. F. L., & Holgado, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146427
Kalia, P., Kaur, N., & Yadav, S. S. (2026) · Wiley eBooks · doi:10.1002/9781394376490.ch11
Corallo, S., Cicerone, O., Brigati, C., Pagani, A., Colletto, L., Pellizzari, B., Pedrazzoli, P., & Maestri, M. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105515 · Cited by 1
Li, S., Li, J., Bu, X., Han, M., & Shi, G. (2026) · Human Cell · doi:10.1007/s13577-026-01435-8
Yildiz, N. D., Arslan, Ç., Ökten, I. N., Kefeli, U., Yıldırım, M. E., Karadurmus, N., Baydas, T., Karabulut, B., Çiçin, İ., Bilir, C., et al. (2026) · Clinics and Practice · doi:10.3390/clinpract16090158
Sagawa, T., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01564-1
Liu, Y., Zhang, Y., Lin, R., Chen, X., Wang, J., Yang, M., Qu, X., Li, Y., Li, J., Zhang, W., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02938-4 · Cited by 1
Lago, N. M., López, M. R., Martínez, M. C. R., Peraita, S. L., Gómez, B. G., Antonilli, C., Ghanem, I., Martelo, M. P., Alfonso, A. L., Montés, A. F., et al. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100404
Uehara, S., Suzuki, T., Kato, J., Asai, H., Kato, A., Harata, S., Ushigome, H., Yamakawa, Y., Hirokawa, T., Takahashi, H., et al. (2026) · Cancer Reports · doi:10.1002/cnr2.70668
Chen, R., Yang, D., & Xu, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1905769
Wang, J., Sun, Y., Chen, L., Wang, Z., Li, K., Guo, Y., Yao, L., Duan, L., & Liu, Q. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-119746
Rodrigues, P. E., & da Silva, M. J. S. (2025) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2025v71n3.5223en
Rodrigues, P. E., & da Silva, M. J. S. (2025) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2025v71n3.5223es
Chemotherapy and Surgical Outcomes for Ovarian Metastases From Colorectal Cancer
Weil, J. B. E., & Goodman, A. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.3634
Raza, A., Qadri, M., Fatima, F., Ullah, M. S., Ansab, M., Fatima, M., Sadiq, Z., Qureshi, Z., & Kahlon, N. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01595-8
“…additional factors, such as tumor location (left vs. right-sided) and molecular characteristics, rather than intrinsic differences in efficacy, is the CALGB 80,405 trial, which found no significant difference in OS between the two biologics when combined with different chemotherapy backbones [ 22].”
Kalil, J. A., Adam, R. A., Meti, N., & Metrakos, P. P. (2026) · Cancers · doi:10.3390/cancers18193169
“The FIRE-3, CALGB/SWOG 80405, TRIBE, and PARADIGM trials enrolled heterogeneous populations with varying https://doi.org/10.3390/cancers18193169 metastatic disease distribution, and conversion to resection was typically a secondary or exploratory endpoint [7,8,66,71].”
InfluentialAbidoye, O., Ou, F., Ulrich, A., McCue, S. A., Sonbol, M. B., Wender, D. B., Klute, K., Jin, Z., Lenz, H., Strickler, J. H., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag307
Self-citationDžunić, M., Petković, I., Cvetanović, A., Stojanovic, M. P., Nikolić, I., Marković, M., Conić, I., & Krtinić, D. (2026) · Cancers · doi:10.3390/cancers18213489
Metadata
- Authors
- Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., Berry, S., Polite, B. N., O'Reilly, E. M., Goldberg, R. M., Hochster, H. S., Schilsky, R. L., Bertagnolli, M. M., El-Khoueiry, A. B., Watson, P., Benson, A. B., Mulkerin, D. L., Mayer, R. J., & Blanke, C.
- Affiliations
- University of California, San Francisco (US)
- Duke University (US)
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- Mayo Clinic (US)
- Dana-Farber/Partners CancerCare, Boston, Massachusetts
- Indiana University, Simon Cancer Center, Indianapolis
- Southeastern Medical Oncology Center (US)
- Sunnybrook Health Science Centre (CA)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Memorial Sloan Kettering Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut
- American Society of Clinical Oncology (US)
- Brigham and Women's Hospital (US)
- Kinston Medical Specialists (US)
- Northwestern University (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-06-20
- Volume
- 317
- Issue
- 23
- Pages
- 2392
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5545896
- OpenAlex
- W2712978371
- Cited by
- 898
- References
- 24
- Citations by year
- 2026: 66 · 2025: 76 · 2024: 87 · 2023: 104 · 2022: 118 · 2021: 118 · 2020: 122 · 2019: 107 · 2018: 82 · 2017: 16
- FWCI
- 39.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (U10CA180882, K05CA169384, U10CA180820, U10CA180791, U10CA180888, U10CA180836, U10CA180790, U10CA180830, U10CA180795, U10CA180850, R01CA149222, U10CA180838, U10CA180867, U10CA180821, U10CA180799)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, KRAS wild-type, cetuximab, bevacizumab, first-line chemotherapy, mFOLFOX6, FOLFIRI, oxaliplatin, irinotecan, monoclonal antibodies, overall survival, progression-free survival, anti-EGFR therapy, anti-VEGF therapy, community oncology
- MeSH terms
- Bevacizumab, Cetuximab, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Canada, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Organoplatinum Compounds, Genes, ras, United States, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Angiogenesis Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
